410 related articles for article (PubMed ID: 18215140)
1. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.
Rapti M; Atkinson SJ; Lee MH; Trim A; Moss M; Murphy G
Biochem J; 2008 Apr; 411(2):433-9. PubMed ID: 18215140
[TBL] [Abstract][Full Text] [Related]
2. ADAM17 co-purifies with TIMP-3 and modulates endothelial invasion responses in three-dimensional collagen matrices.
Kwak HI; Mendoza EA; Bayless KJ
Matrix Biol; 2009 Oct; 28(8):470-9. PubMed ID: 19666115
[TBL] [Abstract][Full Text] [Related]
3. Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10.
Schelter F; Grandl M; Seubert B; Schaten S; Hauser S; Gerg M; Boccaccio C; Comoglio P; Krüger A
Clin Exp Metastasis; 2011 Dec; 28(8):793-802. PubMed ID: 21789719
[TBL] [Abstract][Full Text] [Related]
4. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
[TBL] [Abstract][Full Text] [Related]
5. Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts.
Mezyk-Kopeć R; Bzowska M; Stalińska K; Chełmicki T; Podkalicki M; Jucha J; Kowalczyk K; Mak P; Bereta J
Cytokine; 2009 Jun; 46(3):309-15. PubMed ID: 19346138
[TBL] [Abstract][Full Text] [Related]
6. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
7. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy.
Fedak PW; Moravec CS; McCarthy PM; Altamentova SM; Wong AP; Skrtic M; Verma S; Weisel RD; Li RK
Circulation; 2006 Jan; 113(2):238-45. PubMed ID: 16401770
[TBL] [Abstract][Full Text] [Related]
8. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
Pruessmeyer J; Ludwig A
Semin Cell Dev Biol; 2009 Apr; 20(2):164-74. PubMed ID: 18951988
[TBL] [Abstract][Full Text] [Related]
9. The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?
Saftig P; Reiss K
Eur J Cell Biol; 2011; 90(6-7):527-35. PubMed ID: 21194787
[TBL] [Abstract][Full Text] [Related]
10. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3.
Amour A; Knight CG; Webster A; Slocombe PM; Stephens PE; Knäuper V; Docherty AJ; Murphy G
FEBS Lett; 2000 May; 473(3):275-9. PubMed ID: 10818225
[TBL] [Abstract][Full Text] [Related]
11. Shedding of klotho by ADAMs in the kidney.
van Loon EP; Pulskens WP; van der Hagen EA; Lavrijsen M; Vervloet MG; van Goor H; Bindels RJ; Hoenderop JG
Am J Physiol Renal Physiol; 2015 Aug; 309(4):F359-68. PubMed ID: 26155844
[TBL] [Abstract][Full Text] [Related]
12. The role of CXCL16 and its processing metalloproteinases ADAM10 and ADAM17 in the proliferation and migration of human mesangial cells.
Schramme A; Abdel-Bakky MS; Kämpfer-Kolb N; Pfeilschifter J; Gutwein P
Biochem Biophys Res Commun; 2008 May; 370(2):311-6. PubMed ID: 18373975
[TBL] [Abstract][Full Text] [Related]
13. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
[TBL] [Abstract][Full Text] [Related]
14. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening.
Moss ML; Rasmussen FH
Anal Biochem; 2007 Jul; 366(2):144-8. PubMed ID: 17548045
[TBL] [Abstract][Full Text] [Related]
15. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events.
Moss ML; Bomar M; Liu Q; Sage H; Dempsey P; Lenhart PM; Gillispie PA; Stoeck A; Wildeboer D; Bartsch JW; Palmisano R; Zhou P
J Biol Chem; 2007 Dec; 282(49):35712-21. PubMed ID: 17895248
[TBL] [Abstract][Full Text] [Related]
16. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases.
Gardiner EE; Karunakaran D; Shen Y; Arthur JF; Andrews RK; Berndt MC
J Thromb Haemost; 2007 Jul; 5(7):1530-7. PubMed ID: 17445093
[TBL] [Abstract][Full Text] [Related]
17. ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha.
Le Gall SM; Bobé P; Reiss K; Horiuchi K; Niu XD; Lundell D; Gibb DR; Conrad D; Saftig P; Blobel CP
Mol Biol Cell; 2009 Mar; 20(6):1785-94. PubMed ID: 19158376
[TBL] [Abstract][Full Text] [Related]
18. Ectodomain shedding of CD200 from the B-CLL cell surface is regulated by ADAM28 expression.
Twito T; Chen Z; Khatri I; Wong K; Spaner D; Gorczynski R
Leuk Res; 2013 Jul; 37(7):816-21. PubMed ID: 23643150
[TBL] [Abstract][Full Text] [Related]
19. Acetylenic inhibitors of ADAM10 and ADAM17: in silico analysis of potency and selectivity.
Healy EF; Romano P; Mejia M; Lindfors G
J Mol Graph Model; 2010 Nov; 29(3):436-42. PubMed ID: 20863729
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates.
Minond D; Cudic M; Bionda N; Giulianotti M; Maida L; Houghten RA; Fields GB
J Biol Chem; 2012 Oct; 287(43):36473-87. PubMed ID: 22927435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
